494
Participants
Start Date
April 30, 2007
Primary Completion Date
September 30, 2011
Study Completion Date
August 31, 2012
Epi-Rad90™ Ophthalmic System
A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
ranibizumab
Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
Retina Research Unit of Wills Eye Hospital, Philadelphia
Charlotte Eye Ear Nose & Throat Associates, Charlotte
Southeast Retina Center, Augusta
Retina Group of Florida, Fort Lauderdale
Tennessee Retina, Nashville
Paducah Retinal Center, Paducah
Cincinnati Eye Institute, Cincinnati
Associated Retinal Consultants / William Beaumont Hospital, Royal Oak
University of Wisconsin, Madison
Eye Foundation of Kansas City, Kansas City
Sourasky Medical Center, Tel Aviv
Medical Center Ophthalmology Associates, San Antonio
Retina & Uveitis Consultants of Texas, San Antonio
Austin Retina Associates, Austin
Retina Research Center, Austin
Rocky Mountain Retina Consultants, Salt Lake City
Retinal Consultants of Arizona, Phoenix
Retina Center, PC, Tucson
Retina-Vitreous Associates Medical, Beverly Hills
Northern California Retina Vitreous Associates, Mountain View
UCSF Koret Vision Center, San Francisco
Retinal Diagnostic Center, Campbell
Retina Institute of Hawaii, Honolulu
Universitätsklinik und polyklinik für Augenkranke, Würzburg
New England Eye Center-Tufts University, Boston
Augenklinik Graz, Graz
Institute of Clinical Science, Ophthalmic Research Centre, Royal Victoria Hospital, Belfast
Oftalmo Salud Eye Institute, Lima
Institutio de Microcirugia Ocular-Barcelona, Barcelona
Kings College Hospital, London
Klinik und Poliklinik für Augenheilkunde der Universität Leipzig AöR, Leipzig
University of Geneva, Geneva
Lead Sponsor
NeoVista
INDUSTRY